Search

Your search keyword '"Monge, Susana"' showing total 337 results
Start Over Author "Monge, Susana"
337 results on '"Monge, Susana"'

2. Lifting COVID-19 mitigation measures in Spain (May–June 2020)

Author

Monge, Susana, Latasa Zamalloa, Pello, Sierra Moros, María José, Pérez Olaso, Oscar, García San Miguel, Lucía, Varela, Carmen, Rivera Ariza, Silvia, Vázquez Torres, María C., Olmedo Lucerón, María del Carmen, González Yuste, Paloma, Soler Crespo, Pilar, Segura del Pozo, Javier, Gullón, Pedro, Carrasco, José Miguel, Martínez Sánchez, Elena Vanessa, Redondo Bravo, Lidia, Pichiule Castañeda, Myriam, Purriños Hermida, María Jesús, Hervada Vidal, Xurxo, Huerta Gonzalez, Ismael, Margolles, Mario, Vanaclocha Luna, Hermelinda, Ramalle Gómara, Enrique, Pérez Martín, Jaime Jesús, Chirlaque López, María Dolores, López Fernández, María Jesús, Lorusso, Nicola, Carmona Ubago, Alberto, Rivas Perez, Ana, Ramos Marin, Violeta, Criado Alvarez, Juan José, Castrillejo Pérez, Daniel, Góméz Anés, Atanasio A., Frontera, Marga, Macias Rodriguez, Pedro, Álvarez León, Eva Elisa, Díaz Casañas, Miriam, Lopaz Perez, Maria Angeles, Alonso Pérez de Ágreda, Juan Pablo, Navas Gutierrez, Paloma, Rosell Aguilar, Ignacio, Arteagoitia Axpe, Jose María, Gonzalez Carril, Fernando, Aparicio Azcárraga, Pilar, Simón Soria, Fernando, and Suarez Rodríguez, Berta

Published
2023
Full Text
View/download PDF

3. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study

Author

Moreno, David, Méndez Díaz, Manuel, Huerta González, Ismael, Galmés Truyols, Antònia, Barreno Estévez, Ana, García Velasco, Valvanuz, Rodríguez Recio, Mª Jesús, Sacristán, José, Martínez Marcos, Montserrat, Pastor Villalba, Eliseo, Macías Ortiz, María José, García Vallejo, Ana, Sánchez Gómez, Amaya, García Pina, Rocío, Barricarte Gurea, Aurelio, Sancho Martínez, Rosa, Ochoa, Eva María, Vázquez Cantero, Mauricio, Gómez Anés, Atanasio, Pareja Megía, María Jesús, Castán, Yolanda, Fonseca Álvarez, Manuel Roberto, Salvà Fiol, Antonia, Sánchez Janáriz, Hilda, López Arce, Luz, Cisneros Martín, María Ángeles, Gibernau, Frederic Jose, Fernandez Buey, Cesar, Villatoro Bongiorno, Katja, Rubio García, Francisco Javier, Santos Guerra, Fernando, Astray Mochales, Jenaro, Francisco Verdu, Francisco Javier, García Romero, Isabel, Oriza Bernal, Rosa, Gómez Pérez, Tomás, Hijano Villegas, Salomé, Román Soto, Sergio, Gómez-Barroso, Diana, Lapeña, María Fé, Yagüe Galaup, Virgilio, Alfaro Latorre, Mercedes, Aguilera Guzmán, Marta, Crespo Sánchez-Eznarriaga, Belén, Neira León, Montserrat, Cívicos Villa, Noemí, Monge, Susana, Rojas-Benedicto, Ayelén, Olmedo, Carmen, Mazagatos, Clara, José Sierra, María, Limia, Aurora, Martín-Merino, Elisa, Larrauri, Amparo, and Hernán, Miguel A

Published
2022
Full Text
View/download PDF

4. Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022.

Author

Colombe, Soledad, Funke, Silvia, Koch, Anders, Haverkate, Manon, Monge, Susana, Barret, Anne-Sophie, Vaughan, Aisling, Hahné, Susan, van Ewijk, Catharina, Emborg, Hanne-Dorthe, von Schreeb, Sebastian, Díaz, Asunción, Olmedo, Carmen, Zanetti, Laura, Levy-Bruhl, Daniel, Alves de Sousa, Luis, Hagan, José, Nicolay, Nathalie, and Pebody, Richard

Published
2024
Full Text
View/download PDF

5. Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain

Author

Monge, Susana, Olmedo, Carmen, Alejos, Belen, Lapena, Maria Fe, Sierra, Maria Jose, and Limia, Aurora

Subjects
Epidemics -- Forecasts and trends -- United States, Long-term care facilities -- Management, Company business management, Market trend/market analysis, Health
Abstract

From the beginning of the coronavirus disease (COVID-19) pandemic through March 7, 2021, a total of 18,927 residents in long-term care facilities (LTCF) in Spain died from confirmed COVID-19, resulting [...]

Published
2021
Full Text
View/download PDF

6. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Author

Judd, Ali, Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle Mary, Ghosn, Jade, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Fätkenheuer, Gerd, Julia, Del Amo, Obel, Niels, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pérez-Hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera-Julian, Antoni, Antinori, Andrea, Monforte, Antonella d’Arminio, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo Rojo, Soriano-Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miró, Jose M, Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Quiros-Roldan, Eugenia, Sabin, Caroline, Teira, Ramon, Garrido, Myriam, Haerry, David, de Wit, Stéphane, Costagliola, Dominique, d’Arminio-Monforte, Antonella, del Amo, Julia, Raben, Dorthe, Chêne, Geneviève, Rojo, Conejo Pablo, Barger, Diana, Schwimmer, Christine, Termote, Monique, Campbell, Maria, Frederiksen, Casper M, Friis-Møller, Nina, Kjaer, Jesper, Brandt, Rikke Salbøl, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Cozzi-Lepri, Alessandro, Davies, Mary-Anne, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Grabar, Sophie, Guiguet, Marguerite, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Miro, Jose M, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Rohner, Eliane, and Schomaker, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Sexually Transmitted Infections, Rare Diseases, Emerging Infectious Diseases, Infectious Diseases, HIV/AIDS, Infection, Adolescent, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Risk Factors, Sarcoma, Kaposi, Viral Load, Young Adult, AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord, HIV, Kaposi sarcoma, antiretroviral therapy, cohort study, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundWe compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America.MethodsWe included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs).ResultsWe included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were

Published
2017

7. Estimación de la incidencia real de la COVID-19 en España

Author

Cublier Martínez, Aymar, primary, Gómez-Barroso, Diana, additional, Delgado-Sanz, Concepción, additional, Monge, Susana, additional, Cascajo, Alberto, additional, Marinescu, María Cristina, additional, Larrauri, Amparo, additional, Carretero, Jesús, additional, and E. Singh, David, additional

Published
2024
Full Text
View/download PDF

10. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.

Author

Mazagatos, Clara, Mendioroz, Jacobo, Rumayor, Mercedes Belén, Gallardo García, Virtudes, Álvarez Río, Virginia, Cebollada Gracia, Ana Delia, Batalla Rebollo, Noa, Barranco Boada, María Isabel, Pérez‐Martínez, Olaia, Lameiras Azevedo, Ana Sofía, López González‐Coviella, Nieves, Castrillejo, Daniel, Fernández Ibáñez, Ana, Giménez Duran, Jaume, Ramírez Córcoles, Cristina, Ramos Marín, Violeta, Larrauri, Amparo, Monge, Susana, Basile, Luca, and García Comas, Luis

Subjects
RESPIRATORY syncytial virus infections, HOSPITAL admission & discharge, CHILDREN'S hospitals, HUMAN metapneumovirus infection, RESPIRATORY infections
Abstract

Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods: Estimated RSV hospitalisations in < 1‐year‐olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results: We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study.

Author

Monge, Susana, Humphreys, James, Nicolay, Nathalie, Braeye, Toon, Van Evercooren, Izaak, Holm Hansen, Christian, Emborg, Hanne‐Dorthe, Sacco, Chiara, Mateo‐Urdiales, Alberto, Castilla, Jesús, Martínez‐Baz, Iván, de Gier, Brechje, Hahné, Susan, Meijerink, Hinta, Kristoffersen, Anja Bråthen, Machado, Ausenda, Soares, Patricia, Nardone, Anthony, Bacci, Sabrina, and Kissling, Esther

Subjects
*COVID-19 pandemic, *SARS-CoV-2 Omicron variant, *COVID-19 vaccines, *VACCINE effectiveness, *ELECTRONIC records
Abstract

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV–Infected Adults

Author

Montejano, Rocio, Stella-Ascariz, Natalia, Monge, Susana, Bernardino, José I., Pérez-Valero, Ignacio, Montes, Maria Luisa, Valencia, Eulalia, Martín-Carbonero, Luz, Moreno, Victoria, González-Garcia, Juan, Rodriguez-Centeno, Javier, Rodes, Berta, Cantos, Andres Esteban, Alejos, Belen, de Miguel, Rosa, Arnalich, Francisco, Perona, Rosario, and Arribas, José R.

Published
2018

13. Estimación de la incidencia real de la COVID-19 en España Real COVID-19 incidence rate estimate in Spain.

Author

Martínez, Aymar Cublier, Gómez-Barroso, Diana, Delgado-Sanz, Concepción, Monge, Susana, Cascajo, Alberto, Marinescu, María Cristina, Larrauri, Amparo, Carretero, Jesús, and Singh, David E.

Subjects
WORLD Wide Web, MEDICAL information storage & retrieval systems, TIME series analysis, DESCRIPTIVE statistics, COMMUNICATION, ELECTRONIC health records, COVID-19, DISEASE incidence, ACCESS to information
Abstract

Copyright of Revista Espanola de Comunicacion en Salud is the property of Asociacion Espanola de Comunicacion Sanitaria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

16. Reduction in the risk of mpox infection after MVA-BN vaccination in individuals on HIV pre-exposure prophylaxis: a Spanish cohort study

Author

Fontan-Vela, Mario, primary, Hernando, Victoria, additional, Olmedo, Carmen, additional, Coma, Ermengol, additional, Martinez, Montse, additional, Moreno, David, additional, Lorusso, Nicola, additional, Vazquez Torres, Maria, additional, Barbas del Buey, Jose Francisco, additional, Roig, Javier, additional, Pastor, Eliseo, additional, Galmes Truyols, Antonia, additional, Artigues Serra, Francisca, additional, Sancho Martinez, Rosa Maria, additional, Latasa Zamalloa, Pello, additional, Perez Martinez, Olaia, additional, Vazquez Estepa, Ana, additional, Garcia Rojas, Amos, additional, Barreno Estevez, Ana Isabel, additional, Sanchez-Migallon Naranjo, Alonso, additional, Perez Martin, Jaime Jesus, additional, Peces Jimenez, Pilar, additional, Morales Romero, Raquel, additional, Castilla, Jesus, additional, Garcia Cenoz, Manuel, additional, Huerta, Marta, additional, Boone, An Lieve Dirk, additional, Macias Ortiz, Maria Jose, additional, Alvarez Rio, Virginia, additional, Rodriguez Recio, Maria Jesus, additional, Merino Diaz, Maria, additional, Berradre Saenz, Belen, additional, Teresa-Villegas, Maria, additional, Limia, Aurora, additional, Diaz, Asuncion, additional, and Monge, Susana, additional

Published
2023
Full Text
View/download PDF

17. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65-years-old population in six European countries, October 2021 to November 2022

Author

Kislaya, Irina, primary, Sentís, Alexis, additional, Starrfelt, Jostein, additional, Nunes, Baltasar, additional, Martínez-Baz, Iván, additional, Nielsen, Katrine Finderup, additional, AlKerwi, Ala'a, additional, Braeye, Toon, additional, Fontán-Vela, Mario, additional, Bacci, Sabrina, additional, Meijerink, Hinta, additional, Castilla, Jesus, additional, Emborg, Hanne-Dorthe, additional, Hansen, Christian Holm, additional, Schmitz, Susanne, additional, Valenciano, Marta, additional, Evercooren, Izaak Van, additional, Nardone, Anthony, additional, Nicolay, Nathalie, additional, and Monge, Susana, additional

Published
2023
Full Text
View/download PDF

18. Use of Ambulance Dispatch Calls for Surveillance of Severe Acute Respiratory Infections

Author

Monge, Susana, Duijster, Janneke, Kommer, Geert Jan, van de Kassteele, Jan, Donker, Ge. A., Krafft, Thomas, Engelen, Paul, Valk, Jens P., de Waard, Jan, de Nooij, Jan, van der Hoek, Wim, and van Asten, Liselotte

Subjects
Influenza -- Health aspects, Death, Time, Infection, Public health, Respiratory tract diseases, Diseases, Health, World Health Organization
Abstract

Influenza virus infection is associated with severe illness and death and causes a high burden of disease (1). The World Health Organization recommends that countries improve surveillance of severe influenza [...]

Published
2020
Full Text
View/download PDF

19. North Atlantic oscillation signatures in Western Iberian tree-rings

Author

Roig, Fidel A., Barriopedro Cepero, David, García Herrera, Ricardo, Patón Dominguez, Daniel, Monge, Susana, Roig, Fidel A., Barriopedro Cepero, David, García Herrera, Ricardo, Patón Dominguez, Daniel, and Monge, Susana

Abstract

© The authors 2009. Journal compilation © 2009 Swedish Society for Anthropology and Geography. We appreciate the support from Ricardo Trigo and the Instituto Nacional de Meteorología of Spain who provided the rainfall data from the Lisbon and Hervás meteorological stations, respectively. The authors would like to thank Agustín García who kindly assisted with the fieldwork, and Rafael Bottero and Judy Boshowen for technical assistance., Exactly dated ring-width chronologies derived from Pyrenean oak and sweet chestnut trees growing in northern Extremadura, Spain, were evaluated for their potential as proxies for regional precipitation and North Atlantic Oscillation variability. The relationships among tree-rings, instrumental climatic records, and three versions of the NAO index were computed for different time subperiods over the last century. The results indicate that tree-ring records reflect, with variable intensity, both short-term and long-term variations in climate. Multiple correlation and regression analysis revealed that summer precipitation appeared to be the major factor affecting tree growth at inter-annual timescales. Moreover, since fluctuations in accumulated variability in annual rainfall over southwest Iberia are controlled by winter precipitation, the accumulated rainfall (August of the year n-1 to July of year n) and winter NAO indices are also strongly correlated with tree-ring records at interdecadal timescales. This relationship appears to be especially strong during the second half of the 20th century, which is consistent with an increase of the NAO signal in the annual precipitation during the later part of the century. These results indicate that tree-rings from western Iberia are potential proxies of the NAO variability, useful to be included in palaeoclimatic model studies., Depto. de Física de la Tierra y Astrofísica, Fac. de Ciencias Físicas, TRUE, pub

Published
2023

20. Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021)

Author

Barbeito, Inés, Precioso, Daniel, Sierra, María José, Vegas-Azcárate, Susana, Fernández-Balbuena, Sonia, Vitoriano, Begoña, Gómez-Ullate, David, Cao, Ricardo, Monge, Susana, Barbeito, Inés, Precioso, Daniel, Sierra, María José, Vegas-Azcárate, Susana, Fernández-Balbuena, Sonia, Vitoriano, Begoña, Gómez-Ullate, David, Cao, Ricardo, and Monge, Susana

Abstract

[Abstract]: Background: We estimated the association between the level of restriction in nine different fields of activity and SARS-CoV-2 transmissibility in Spain, from 15 September 2020 to 9 May 2021. Methods: A stringency index (0–1) was created for each Spanish province (n = 50) daily. A hierarchical multiplicative model was fitted. The median of coefficients across provinces (95% bootstrap confidence intervals) quantified the effect of increasing one standard deviation in the stringency index over the logarithmic return of the weekly percentage variation of the 7-days SARS-CoV-2 cumulative incidence, lagged 12 days. Results: Overall, increasing restrictions reduced SARS-CoV-2 transmission by 22% (RR = 0.78; one-sided 95%CI: 0, 0.82) in 1 week, with highest effects for culture and leisure 14% (0.86; 0, 0.98), social distancing 13% (0.87; 0, 0.95), indoor restaurants 10% (0.90; 0, 0.95) and indoor sports 6% (0.94; 0, 0.98). In a reduced model with seven fields, culture and leisure no longer had a significant effect while ceremonies decreased transmission by 5% (0.95; 0, 0.96). Models R2 was around 70%. Conclusion: Increased restrictions decreased COVID-19 transmission. Limitations include remaining collinearity between fields, and somewhat artificial quantification of qualitative restrictions, so the exact attribution of the effect to specific areas must be done with caution. Copyright © 2023 Barbeito, Precioso, Sierra, Vegas-Azcárate, Fernández Balbuena, Vitoriano, Goméz-Ullate, Cao, Monge and the Study Group for Non-Pharmaceutical Interventions in Spain.

Published
2023

22. Monitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Author

Kislaya, Irina, Sentís, Alexis, Starrfelt, Jostein, Nunes, Baltazar, Martínez‐Baz, Iván, Nielsen, Katrine Finderup, AlKerwi, Ala'a, Braeye, Toon, Fontán‐Vela, Mario, Bacci, Sabrina, Meijerink, Hinta, Castilla, Jesús, Emborg, Hanne‐Dorthe, Hansen, Christian Holm, Schmitz, Susanne, Van Evercooren, Izaak, Valenciano, Marta, Nardone, Anthony, Nicolay, Nathalie, and Monge, Susana

Subjects
VACCINE effectiveness, COVID-19 vaccines, COVID-19, HOSPITAL care, BOOSTER vaccines, ELECTRONIC surveillance, FRAIL elderly
Abstract

Background: Within the ECDC‐VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID‐19 hospitalisation and COVID‐19‐related death using electronic health registries (EHR), between October 2021 and November 2022, in community‐dwelling residents aged 65–79 and ≥80 years in six European countries. Methods: EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8‐week follow‐up periods, allowing 1 month‐lag for data consolidation. Cox proportional‐hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 − aHR) × 100%. Site‐specific estimates were pooled using random‐effects meta‐analysis. Results: For ≥80 years, considering unvaccinated as the reference, VE against COVID‐19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: −27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65–79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: −3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65–79 years. The first booster VE against COVID‐19‐related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions: Successive vaccine boosters played a relevant role in maintaining protection against COVID‐19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near‐real‐time VE monitoring in the EU/EEA and support public health decision‐making. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. HIV testing history and access to treatment among migrants living with HIV in Europe

Author

Fakoya, Ibidun, Arco, Debora Alvarez-Del, Monge, Susana, Copas, Andrew J., Gennotte, Anne-Francoise, Anne, Alain Volny, Wengenroth, Claudia, Touloumi, Giota, Prins, Maria, Barros, Henrique, Darling, Katharine E.A., Prestileo, Tullio, Del Amo, Julia, and Burns, Fiona M.

Subjects
Medical records -- Analysis, HIV tests -- Analysis, Health care industry -- Analysis, HIV -- Prevention -- Care and treatment -- Diagnosis, Health care services accessibility -- Analysis, Environmental refugees -- Health aspects -- Demographic aspects, Health care industry, Health, European Union
Abstract

Introduction: Migrants are overrepresented in the European HIV epidemic. We aimed to understand the barriers and facilitators to HIV testing and current treatment and healthcare needs of migrants living with HIV in Europe. Methods: A cross-sectional study was conducted in 57 HIV clinics in nine countries (Belgium, Germany, Greece, Italy, The Netherlands, Portugal, Spain, Switzerland and United Kingdom), July 2013 to July 2015. HIV-positive patients were eligible for inclusion if they were as follows: 18 years or older; foreign-born residents and diagnosed within five years of recruitment. Questionnaires were completed electronically in one of 15 languages and linked to clinical records. Primary outcomes were access to primary care and previous negative HIV test. Data were analysed using random effects logistic regression. Outcomes of interest are presented for women, heterosexual men and gay/bisexual men. Results: A total of 2093 respondents (658 women, 446 heterosexual men and 989 gay/bisexual men) were included. The prevalence of a previous negative HIV test was 46.7%, 43.4% and 82.0% for women, heterosexual and gay/bisexual men respectively. In multivariable analysis previous testing was positively associated with: receipt of post-migration antenatal care among women, permanent residency among heterosexual men and identifying as gay rather than bisexual among gay/bisexual men. Access to primary care was found to be high (>83%) in all groups and was strongly associated with country of residence. Late diagnosis was common for women and heterosexual men (60.8% and 67.1%, respectively) despite utilization of health services prior to diagnosis. Across all groups almost three-quarters of people on antiretrovirals had an HIV viral load Conclusions: Migrants access healthcare in Europe and while many migrants had previously tested for HIV, that they went on to test positive at a later date suggests that opportunities for HIV prevention are being missed. Expansion of testing beyond sexual health and antenatal settings is still required and testing opportunities should be linked with combination prevention measures such as access to PrEP and treatment as prevention. Keywords: HIV; migrants; HIV serodiagnosis; primary healthcare; health services accessibility, 1 | INTRODUCTION The HIV epidemic in Europe is characterized by a disproportionate number of infections among migrants. Although foreign citizens only made up 7% of the population of the [...]

Published
2018
Full Text
View/download PDF

26. Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination

Author

Varea-Jiménez, Elena, primary, Aznar Cano, Esteban, additional, Vega-Piris, Lorena, additional, Martínez Sánchez, Elena Vanessa, additional, Mazagatos, Clara, additional, García San Miguel Rodríguez-Alarcón, Lucía, additional, Casas, Inmaculada, additional, Sierra Moros, María José, additional, Iglesias-Caballero, Maria, additional, Vazquez-Morón, Sonia, additional, Larrauri, Amparo, additional, and Monge, Susana, additional

Published
2023
Full Text
View/download PDF

29. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study

Author

Lodi, Sara, Phillips, Andrew, Logan, Roger, Olson, Ashley, Costagliola, Dominique, Abgrall, Sophie, van Sighem, Ard, Reiss, Peter, Miró, José M, Ferrer, Elena, Justice, Amy, Gandhi, Neel, Bucher, Heiner C, Furrer, Hansjakob, Moreno, Santiago, Monge, Susana, Touloumi, Giota, Pantazis, Nikos, Sterne, Jonathan, Young, Jessica G, Meyer, Laurence, Seng, Rémonie, Dabis, Francois, Vandehende, Marie-Anne, Pérez-Hoyos, Santiago, Jarrín, Inma, Jose, Sophie, Sabin, Caroline, and Hernán, Miguel A

Published
2015
Full Text
View/download PDF

30. Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination

Author

Varea-Jiménez, Elena, primary, Aznar Cano, Esteban, additional, Vega-Piris, Lorena, additional, Martínez Sánchez, Elena Vanessa, additional, Mazagatos, Clara, additional, García San Miguel Rodríguez-Alarcón, Lucía, additional, Casas, Inmaculada, additional, Sierra Moros, María José, additional, Iglesias-Caballero, Maria, additional, Vazquez-Morón, Sonia, additional, Larrauri, Amparo, additional, and Monge, Susana, additional

Published
2022
Full Text
View/download PDF

33. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022

Author

Sentís, Alexis, Kislaya, Irina, Nicolay, Nathalie, Meijerink, Hinta, Starrfelt, Jostein, Martínez-Baz, Iván, Castilla, Jesús, Nielsen, Katrine Finderup, Hansen, Christian Holm, Emborg, Hanne-Dorthe, Nardone, Anthony, Derrough, Tarik, Valenciano, Marta, Nunes, Baltazar, Monge, Susana, VEBIS-Lot4 working group, Larrauri, Amparo, Mazagatos, Clara, and European Centre for Disease Prevention and Control

Subjects
Vaccine effectiveness, Delta variant, COVID-19 Vaccines, Epidemiology, Public Health, Environmental and Occupational Health, COVID-19, Vaccine Efficacy, Pilot Projects, Omicron variant, Hospitalization, Vaccination primary course, Virology, Vaccination booster dose, Humans, Registries, Electronics, Aged
Abstract

By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and

Published
2022

34. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study

Author

Monge, Susana, primary, Rojas-Benedicto, Ayelén, additional, Olmedo, Carmen, additional, Mazagatos, Clara, additional, José Sierra, María, additional, Limia, Aurora, additional, Martín-Merino, Elisa, additional, Larrauri, Amparo, additional, Hernán, Miguel A, additional, Moreno, David, additional, Méndez Díaz, Manuel, additional, Huerta González, Ismael, additional, Galmés Truyols, Antònia, additional, Barreno Estévez, Ana, additional, García Velasco, Valvanuz, additional, Rodríguez Recio, Mª Jesús, additional, Sacristán, José, additional, Martínez Marcos, Montserrat, additional, Pastor Villalba, Eliseo, additional, Macías Ortiz, María José, additional, García Vallejo, Ana, additional, Sánchez Gómez, Amaya, additional, García Pina, Rocío, additional, Barricarte Gurea, Aurelio, additional, Sancho Martínez, Rosa, additional, Ochoa, Eva María, additional, Vázquez Cantero, Mauricio, additional, Gómez Anés, Atanasio, additional, Pareja Megía, María Jesús, additional, Castán, Yolanda, additional, Fonseca Álvarez, Manuel Roberto, additional, Salvà Fiol, Antonia, additional, Sánchez Janáriz, Hilda, additional, López Arce, Luz, additional, Cisneros Martín, María Ángeles, additional, Gibernau, Frederic Jose, additional, Fernandez Buey, Cesar, additional, Villatoro Bongiorno, Katja, additional, Rubio García, Francisco Javier, additional, Santos Guerra, Fernando, additional, Astray Mochales, Jenaro, additional, Francisco Verdu, Francisco Javier, additional, García Romero, Isabel, additional, Oriza Bernal, Rosa, additional, Gómez Pérez, Tomás, additional, Hijano Villegas, Salomé, additional, Román Soto, Sergio, additional, Gómez-Barroso, Diana, additional, Lapeña, María Fé, additional, Yagüe Galaup, Virgilio, additional, Alfaro Latorre, Mercedes, additional, Aguilera Guzmán, Marta, additional, Crespo Sánchez-Eznarriaga, Belén, additional, Neira León, Montserrat, additional, and Cívicos Villa, Noemí, additional

Published
2022
Full Text
View/download PDF

35. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion

Author

Stirrup, OT, Copas, AJ, Phillips, AN, Gill, MJ, Geskus, RB, Touloumi, G, Young, J, Bucher, HC, Babiker, AG, Kelleher, Tony, Cooper, David, Grey, Pat, Finlayson, Robert, Bloch, Mark, Kelleher, Tony, Ramacciotti, Tim, Gelgor, Linda, Smith, Don, Zangerle, Robert, Gill, John, Lutsar, Irja, Chêne, Geneviève, Dabis, Francois, Thiebaut, Rodolphe, Costagliola, Dominique, Guiguet, Marguerite, Vanhems, Philippe, Chaix, Marie‐Laure, Ghosn, Jade, Meyer, Laurence, Boufassa, Faroudy, Hamouda, Osamah, Meixenberger, Karolin, Bannert, Norbert, Bartmeyer, Barbara, Antoniadou, Anastasia, Chrysos, Georgios, Daikos, Georgios L., Pantazis, Nikos, Katsarou, Olga, Rezza, Giovanni, Dorrucci, Maria, Monforte, Antonella, Luca, Andrea, Prins, Maria, Geskus, Ronald, Helm, Jannie, Schuitemaker, Hanneke, Sannes, Mette, Brubakk, Oddbjorn, Kran, Anne‐Marte, Rosinska, Magdalena, Muga, Roberto, Tor, Jordi, Olalla, Patricia, Cayla, Joan, Amo, Julia, Moreno, Santiago, Monge, Susana, Amo, Julia, Romero, Jorge, Pérez‐Hoyos, Santiago, Sönnerborg, Anders, Bucher, C, Günthard, Huldrych, Scherrer, Alexandra, Malyuta, Ruslan, Murphy, Gary, Porter, Kholoud, Johnson, Anne, Babiker, Abdel, Pillay, Deenan, Morrison, Charles, Salata, Robert, Mugerwa, Roy, Chipato, Tsungai, Price, Matt A., Gilmour, Jill, Kamali, Anatoli, and Karita, Etienne

Published
2018
Full Text
View/download PDF

36. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance

Author

Lodi, Sara, Günthard, Huldrych F., Dunn, David, Garcia, Federico, Logan, Roger, Jose, Sophie, Bucher, Heiner C., Scherrer, Alexandra U., Schneider, Marie-Paule, Egger, Matthias, Glass, Tracy R., Reiss, Peter, van Sighem, Ard, Boender, T. Sonia, Phillips, Andrew N., Porter, Kholoud, Hawkins, David, Moreno, Santiago, Monge, Susana, Paraskevis, Dimitrios, Simeon, Metallidis, Vourli, Georgia, Sabin, Caroline, and Hernán, Miguel A.

Published
2018
Full Text
View/download PDF

37. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

Author

Monge, S, Mocroft, A, Sabin, A, Touloumi, G, Sighem, A, Abgrall, S, Dray‐Spira, R, Spire, B, Castagna, A, Mussini, C, Zangerle, R, Hessamfar, M, Anderson, J, Hamouda, O, Ehren, K, Obel, N, Kirk, O, Antinori, A, Girardi, E, Saracino, A, Calmy, A, Wit, S, Wittkop, L, Bucher, C, Montoliu, A, Raben, D, Prins, M, Meyer, L, Chene, G, Burns, F, Amo, J, Judd, Ali, Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle, Ghosn, Jade, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Fätkenheuer, Gerd, Amo, Julia, Obel, Niels, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pérez‐Hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera‐Julian, Antoni, Antinori, Andrea, Monforte, Antonella, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo, Soriano‐Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miró, JoseM, Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Torti, Carlo, Sabin, Caroline, Teira, Ramon, Garrido, Myriam, Haerry, David, Wit, Stéphane, Miró, Mª, Costagliola, Dominique, dʼArminio‐Monforte, Antonella, Castagna, Antonella, Amo, Julia, Mocroft, Amanda, Raben, Dorthe, Chêne, Geneviève, Judd, Ali, Conejo, Pablo, Barger, Diana, Schwimmer, Christine, Termote, Monique, Wittkop, Linda, Campbell, Maria, Frederiksen, Casper M, Friis‐Møller, Nina, Kjaer, Jesper, Raben, Dorthe, Brandt, Rikke, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Bucher, Heiner, Cozzi‐Lepri, Alessandro, Dabis, François, Monforte, Antonella, Davies, Mary‐Anne, Amo, Julia, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Grabar, Sophie, Judd, Ali, Kirk, Ole, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Meyer, Laurence, Miró, Jose, Mocroft, Amanda, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Rohner, Eliane, Schomaker, Michael, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Thorne, Claire, Torti, Carlo, Valk, Marc, and Wittkop, Linda

Published
2018
Full Text
View/download PDF

38. HIV incidence in the Estonian population in 2013 determined using the HIV‐1 limiting antigen avidity assay

Author

Soodla, P, Simmons, R, Huik, K, Pauskar, M, Jõgeda, E‐L, Rajasaar, H, Kallaste, E, Maimets, M, Avi, R, Murphy, G, Porter, K, Lutsar, I, Del Amo, Julia, Meyer, Laurence, Bucher, Heiner C., Chêne, Geneviève, Hamouda, Osamah, Pillay, Deenan, Prins, Maria, Rosinska, Magda, Sabin, Caroline, Touloumi, Giota, Olson, Ashley, Cartier, Andrea, Fradette, Lorraine, Walker, Sarah, Babiker, Abdel, De Luca, Andrea, Fisher, Martin, Muga, Roberto, Kelleher, Tony, Cooper, David, Grey, Pat, Finlayson, Robert, Bloch, Mark, Ramacciotti, Tim, Gelgor, Linda, Smith, Don, Zangerle, Robert, Gill, John, Dabis, Francois, Thiebaut, Rodolphe, Costagliola, Dominique, Guiguet, Marguerite, Vanhems, Philippe, Chaix, Marie‐Laure, Ghosn, Jade, Boufassa, Faroudy, Meixenberger, Karolin, Bannert, Norbert, Bartmeyer, Barbara, Antoniadou, Anastasia, Chrysos, Georgios, Daikos, Georgios L., Pantazis, Nikos, Katsarou, Olga, Rezza, Giovanni, Dorrucci, Maria, Monforte, Antonella dʼArminio, Geskus, Ronald, van der Helm, Jannie, Schuitemaker, Hanneke, Sannes, Mette, Brubakk, Oddbjorn, Kran, Anne‐Marte Bakken, Rosinska, Magdalena, Tor, Jordi, de Olalla, Patricia Garcia, Cayla, Joan, Moreno, Santiago, Monge, Susana, del Romero, Jorge, Pérez‐Hoyos, Santiago, Sönnerborg, Anders, Günthard, Huldrych, Scherrer, Alexandra, Malyuta, Ruslan, Johnson, Anne, Phillips, Andrew, Morrison, Charles, Price, Matt A., Giaquinto, Carlo, Grarup, Jesper, Kirk, Ole, Bailey, Heather, Volny Anne, Alain, Panteleev, Alex, Thorne, Claire, Aboulker, Jean‐Pierre, Albert, Jan, Asandi, Silvia, De Wit, Stéphane, Reiss, Peter, Gatell, José, Karpov, Igor, Ledergerber, Bruno, Møller, Claus, Rakhmanova, Aza, Rockstroh, Jürgen, Sandhu, Manjinder, Dedes, Nikos, Pizzuti, David, Faggion, Silvia, Raben, Dorthe, Schwimmer, Christine, and Scott, Martin

Published
2018
Full Text
View/download PDF

39. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus

Author

Ghosn, Jade, Bayan, Tatiana, Meixenberger, Karolin, Tran, Laurent, Frange, Pierre, d’Arminio Monforte, Antonella, Zangerle, Robert, de Mendoza, Carmen, Krastinova, Evguenia, Porter, Kholoud, Meyer, Laurence, Chaix, Marie-Laure, Kelleher, Tony, Cooper, David, Grey, Pat, Finlayson, Robert, Bloch, Mark, Kelleher, Tony, Ramacciotti, Tim, Gelgor, Linda, Cooper, David, Smith, Don, Zangerle, Robert, Gill, John, Lutsar, Irja, Chêne, Geneviève, Dabis, Francois, Thiebaut, Rodolphe, Costagliola, Dominique, Guiguet, Marguerite, Vanhems, Philippe, Chaix, Marie-Laure, Ghosn, Jade, Meyer, Laurence, Boufassa, Faroudy, Hamouda, Osamah, Meixenberger, Karolin, Bannert, Norbert, Bartmeyer, Barbara, Antoniadou, Anastasia, Chrysos, Georgios, Daikos, Georgios L., Touloumi, Giota, Pantazis, Nikos, Katsarou, Olga, Rezza, Giovanni, Dorrucci, Maria, Monforte, Antonella d’Arminio, De Luca, Andrea, Prins, Maria, Geskus, Ronald, van der Helm, Jannie, Schuitemaker, Hanneke, Sannes, Mette, Brubakk, Oddbjorn, Kran, Anne-Marte Bakken, Rosinska, Magdalena, Muga, Roberto, Tor, Jordi, de Olalla, Patricia Garcia, Cayla, Joan, del Amo, Julia, Moreno, Santiago, Monge, Susana, Del Amo, Julia, del Romero, Jorge, Pérez-Hoyos, Santiago, Sönnerborg, Anders, Bucher, Heiner C., Günthard, Huldrych, Scherrer, Alexandra, Malyuta, Ruslan, Murphy, Gary, Porter, Kholoud, Johnson, Anne, Phillips, Andrew, Babiker, Abdel, Pillay, Deenan, Morrison, Charles, Salata, Robert, Mugerwa, Roy, Chipato, Tsungai, Price, Matt A., Gilmour, Jill, Kamali, Anatoli, and Karita, Etienne

Published
2017
Full Text
View/download PDF

40. Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020 - May 2021)

Author

Barbeito, Inés, primary, Precioso, Daniel, additional, Sierra, María José, additional, Vegas-Azcárate, Susana, additional, Balbuena, Sonia Fernández, additional, Vitoriano, Begoña, additional, Goméz-Ullate, David, additional, Cao, Ricardo, additional, Monge, Susana, additional, and Spain, Study Group for Non-Pharmaceutical Interventions in, additional

Published
2022
Full Text
View/download PDF

42. Higher rates of triple‐class virological failure in perinatally HIV‐infected teenagers compared with heterosexually infected young adults in Europe

Author

Judd, A, Lodwick, R, NogueraJulian, A, Gibb, DM, Butler, K, Costagliola, D, Sabin, C, van Sighem, A, Ledergerber, B, Torti, C, Mocroft, A, Podzamczer, D, Dorrucci, M, De Wit, S, Obel, N, Dabis, F, CozziLepri, A, García, F, Brockmeyer, NH, Warszawski, J, GonzalezTome, MI, Mussini, C, Touloumi, G, Zangerle, R, Ghosn, J, Castagna, A, Fätkenheuer, G, Stephan, C, Meyer, L, Campbell, MA, Chene, G, Phillips, A, Mary Krause, Murielle, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Amo, Julia Del, Thorne, Claire, Kirk, Ole, PérezHoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Antinori, Andrea, Monforte, Antonella dʼArminio, Prieto, Luis, Rojo, Pablo, SorianoArandes, Antoni, Battegay, Manuel, Kouyos, Roger, Tookey, Pat, Casabona, Jordi, Miró, Jose M., Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Teira, Ramon, Garrido, Myriam, Haerry, David, Raben, Dorthe, Chêne, Geneviève, Barger, Diana, Schwimmer, Christine, Termote, Monique, Frederiksen, Casper M., FriisMøller, Nina, Kjaer, Jesper, Salbøl Brandt, Rikke, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Davies, MaryAnne, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Grabar, Sophie, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Puoti, Massimo, Schomaker, Michael, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Thorne, Claire, van der Valk, Marc, and Wyss, Natasha

Published
2017
Full Text
View/download PDF

44. Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants.

Author

Monge, Susana, Rojas-Benedicto, Ayelén, Olmedo, Carmen, Martín-Merino, Elisa, Mazagatos, Clara, Limia, Aurora, Sierra, María José, Larrauri, Amparo, Hernán, Miguel A, and IBERCovid

Subjects
*DRUG efficacy, *COVID-19, *IMMUNIZATION, *CONFIDENCE intervals, *COVID-19 vaccines, *REINFECTION, *TREATMENT effectiveness, *MESSENGER RNA, *INDEPENDENT living, *KAPLAN-Meier estimator, *EVALUATION
Abstract

Background Single-dose vaccination was widely recommended in the pre-Omicron era for persons with previous SARS-CoV-2 infection. The effectiveness of a second vaccine dose in this group in the Omicron era is unknown. Methods We linked nationwide population registries in Spain to identify community-dwelling individuals aged 18–64, with a positive SARS-CoV-2 test before single-dose mRNA vaccination (mRNA-1273 or BNT162b2). Every day between 3 January and 6 February 2022 we matched 1:1 individuals receiving a second mRNA vaccine dose and controls on sex, age, province, first dose type and time, month of primary infection, and number of previous tests. We then estimated Kaplan–Meier risks of confirmed SARS-CoV-2 reinfection. We performed a similar analysis in a Delta-dominant period, between 19 July and 30 November 2021. Results In the Omicron period, estimated effectiveness (95% CI) of a second dose was 62.2% (58.2–66.4%) 7–34 days after administration, similar across groups defined by age, sex, type of first vaccine, and time since the first dose. Estimated effectiveness was 65.4% (61.1–69.9%) for mRNA-1273 and 52.0% (41.8–63.1%) for BNT162b2. Estimated effectiveness was 78.5% (67.4–89.9%), 66.1% (54.9–77.5%), and 60.2% (55.5–64.8%) when primary infection had occurred in the Delta, Alpha, and pre-Alpha periods, respectively. In the Delta period, the estimated effectiveness of a second dose was 8.8% (−55.3% to 81.1%). Conclusions Our results suggest that, over 1 month after administration, a second dose of mRNA vaccine increases protection against SARS-CoV-2 reinfection with the Omicron variant among individuals with single-dose vaccination and previously infected with another variant. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test negative design study based on SARI sentinel surveillance in Spain

Author

Ateca, Clara Mazagatos, primary, Delgado-Sanz, Concepción, additional, Monge, Susana, additional, Pozo, Francisco, additional, Oliva, Jesús, additional, Sandonis, Virginia, additional, Gandarillas, Ana, additional, Quiñones-Rubio, Carmen, additional, Ruiz-Sopeña, Cristina, additional, Gallardo-García, Virtudes, additional, Basile, Luca, additional, Barranco-Boada, María Isabel, additional, Hidalgo-Pardo, Olga, additional, Vazquez-Cancela, Olalla, additional, García-Vázquez, Miriam, additional, Fernández-Sierra, Amelia, additional, Milagro-Beamonte, Ana, additional, Ordobás, María, additional, Martínez-Ochoa, Eva, additional, Fernández-Arribas, Socorro, additional, Lorusso, Nicola, additional, Martinez, Ana, additional, García-Fulgueiras, Ana, additional, Sastre-Palou, Bartolomé, additional, Losada-Castillo, Isabel, additional, Martínez-Cuenca, Silvia, additional, Águila, Mar Rodríguez-del, additional, Latorre-Millán, Miriam, additional, and Larrauri, Amparo, additional

Published
2022
Full Text
View/download PDF

48. Medico-legal importance of the complications observed in Monteggia’s fracture

Author

Corrales Monge, Susana

Subjects
codo, luxo-fracture, Fracture, dislocation, bone deviation, luxofractura, luxación, limitación articular, desviación ósea, joint limitation, elbow, Fractura
Abstract

Resumen La Fractura de Monteggia es una lesión caracterizada por una fractura del cúbito en su porción proximal o media junto con una luxación de la cabeza del radio. (1) Es una lesión poco frecuente que representa entre el 5 y el 7% de las fracturas del antebrazo, a pesar de su rareza, siempre ha sido considerada de gran importancia por las comorbilidades que pueden acompañarla, bien por ser tratadas de forma inadecuada o por retraso en su tratamiento médico. Cuando no se diagnostica y trata a tiempo, puede quedar como secuela una limitación de la movilidad articular y una incapacidad funcional importante en la extremidad traumatizada. (2) Es por esta razón que se decide realizar el presente artículo el cual pretende reflejar la importancia de las complicaciones presentadas en la Fractura de Monteggia, al momento de la valoración médico legal, pudiendo requerir incapacidad temporal y permanente dado al tiempo que toma su recuperación, la limitación a la movilización posterior al manejo médico y el dolor residual que puede presentar. Abstract The Monteggia Fracture is an injury characterized by a fracture of the proximal or middle portion of the ulna with a dislocation of the head of the radius. (1) It is a rare injury and represents between 5 and 7% of forearm fractures. Despite its rarity, it has always been considered of great importance due to the comorbidities that can accompany it, either due to being treated inadequately or due to delay in your medical treatment. When it is not diagnosed and treated in time, a limitation of joint mobility and a significant functional disability in the traumatized limb can remain as a consequence. (2) It is for this reason that we decided to carry out this article which reflect the importance of the complication of the Monteggia Fracture, at the time of the legal evaluation, which may require temporary and permanent disability given to the time it takes its recovery, the limitation to mobilization after medical management and the residual pain that it may present.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results